Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines

Gabriele Stengel, Eva Kristina Bee Hautarztpraxis Stengel and Bee, Münster, Germany Abstract: Botulinum toxin type A (BTX-A) preparations are widely used nonsurgical treatments for facial wrinkles. Higher doses of BTX-A are also used for therapeutic purposes in the treatment of conditions...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stengel G, Bee EK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/50e84409bf0040daaa9cca4fcbab2894
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50e84409bf0040daaa9cca4fcbab2894
record_format	dspace
spelling	oai:doaj.org-article:50e84409bf0040daaa9cca4fcbab28942021-12-02T06:58:33ZAntibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines1178-1998https://doaj.org/article/50e84409bf0040daaa9cca4fcbab28942011-11-01T00:00:00Zhttps://www.dovepress.com/antibody-induced-secondary-treatment-failure-in-a-patient-treated-with-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Gabriele Stengel, Eva Kristina Bee Hautarztpraxis Stengel and Bee, Münster, Germany Abstract: Botulinum toxin type A (BTX-A) preparations are widely used nonsurgical treatments for facial wrinkles. Higher doses of BTX-A are also used for therapeutic purposes in the treatment of conditions involving increased muscle tone, such as cervical dystonia. The phenomenon of antibody-induced treatment failure is well known in the therapeutic setting, but reports are also emerging following cosmetic use of BTX-A. We describe the case of a 41-year-old female nurse who developed secondary treatment failure during 6 years of BTX-A treatment for glabellar lines. After a good response to the first BTX-A injection, the intensity and duration of effect decreased after subsequent treatments. Antibody tests revealed a high titer of neutralizing anti-BTX-A antibodies. This case shows secondary treatment failure due to the production of neutralizing antibodies following administration of BTX-A formulations for cosmetic purposes and demonstrates that immunogenicity of BTX-A preparations is an important consideration, even in the cosmetic setting. Keywords: botulinum toxin type A, neutralizing antibodies, antibody-induced treatment failureStengel GBee EKDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 281-284 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Stengel G Bee EK Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
description	Gabriele Stengel, Eva Kristina Bee Hautarztpraxis Stengel and Bee, Münster, Germany Abstract: Botulinum toxin type A (BTX-A) preparations are widely used nonsurgical treatments for facial wrinkles. Higher doses of BTX-A are also used for therapeutic purposes in the treatment of conditions involving increased muscle tone, such as cervical dystonia. The phenomenon of antibody-induced treatment failure is well known in the therapeutic setting, but reports are also emerging following cosmetic use of BTX-A. We describe the case of a 41-year-old female nurse who developed secondary treatment failure during 6 years of BTX-A treatment for glabellar lines. After a good response to the first BTX-A injection, the intensity and duration of effect decreased after subsequent treatments. Antibody tests revealed a high titer of neutralizing anti-BTX-A antibodies. This case shows secondary treatment failure due to the production of neutralizing antibodies following administration of BTX-A formulations for cosmetic purposes and demonstrates that immunogenicity of BTX-A preparations is an important consideration, even in the cosmetic setting. Keywords: botulinum toxin type A, neutralizing antibodies, antibody-induced treatment failure
format	article
author	Stengel G Bee EK
author_facet	Stengel G Bee EK
author_sort	Stengel G
title	Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
title_short	Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
title_full	Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
title_fullStr	Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
title_full_unstemmed	Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
title_sort	antibody-induced secondary treatment failure in a patient treated with botulinum toxin type a for glabellar frown lines
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/50e84409bf0040daaa9cca4fcbab2894
work_keys_str_mv	AT stengelg antibodyinducedsecondarytreatmentfailureinapatienttreatedwithbotulinumtoxintypeaforglabellarfrownlines AT beeek antibodyinducedsecondarytreatmentfailureinapatienttreatedwithbotulinumtoxintypeaforglabellarfrownlines
_version_	1718399630827323392

Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines

Ejemplares similares